APO Research
Talk to an analyst

APO RESEARCH · REPORT

Direct Oral Anticoagulants (DOACs)

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Direct Oral Anticoagulants (DOACs) Industry Growth and Trends Forecast to 2032

28 December 2025107 pages

Choose your research edition.

Industry ResearchDirect Oral Anticoagulants (DOACs) Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Direct Oral Anticoagulants (DOACs) Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Direct Oral Anticoagulants (DOACs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Direct Oral Anticoagulants (DOACs) Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Direct Oral Anticoagulants (DOACs) Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Direct Oral Anticoagulants (DOACs) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Direct Oral Anticoagulants (DOACs) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Direct Oral Anticoagulants (DOACs) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Direct Oral Anticoagulants (DOACs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Direct Oral Anticoagulants (DOACs) include Accord Healthcare, Apotex, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Janssen Pharmaceuticals, Teva Pharmaceutical and Viatris, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Direct Oral Anticoagulants (DOACs) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Direct Oral Anticoagulants (DOACs) market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Direct Oral Anticoagulants (DOACs) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Direct Oral Anticoagulants (DOACs).

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Direct Oral Anticoagulants (DOACs) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Direct Oral Anticoagulants (DOACs) Market by Company

Accord Healthcare

Apotex

Boehringer Ingelheim

Bristol Myers Squibb

Daiichi Sankyo

GlaxoSmithKline

Janssen Pharmaceuticals

Teva Pharmaceutical

Viatris

Bayer

Pfizer

Mylan

Sandoz

Direct Oral Anticoagulants (DOACs) Segment by Type

Oral Factor Xa Inhibitors

Direct Thrombin Inhibitors (DTIs)

Direct Oral Anticoagulants (DOACs) Segment by Application

Pulmonary Embolism

Deep Vein Thrombosis

Atrial Fibrillation

Other

Direct Oral Anticoagulants (DOACs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Direct Oral Anticoagulants (DOACs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Direct Oral Anticoagulants (DOACs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Direct Oral Anticoagulants (DOACs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Direct Oral Anticoagulants (DOACs) manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Direct Oral Anticoagulants (DOACs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Oral Factor Xa Inhibitors Table 2. Major Company of Direct Thrombin Inhibitors (DTIs) Table 3. Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units) Table 5. Global Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Type (2021-2026) Table 6. Global Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (US$ Million) Table 7. Global Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Type (2021-2026) Table 8. Global Direct Oral Anticoagulants (DOACs) Price by Type (2021-2026) & (US$/Unit) Table 9. Global Direct Oral Anticoagulants (DOACs) Sales by Type (2027-2032) & (K Units) Table 10. Global Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Type (2027-2032) Table 11. Global Direct Oral Anticoagulants (DOACs) Sales by Type (2027-2032) & (US$ Million) Table 12. Global Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Type (2027-2032) Table 13. Global Direct Oral Anticoagulants (DOACs) Price by Type (2027-2032) & (US$/Unit) Table 14. North America Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units) Table 15. North America Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units) Table 17. Europe Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units) Table 21. Latin America Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Type (2021-2026) & (US$ Million) Table 24. Direct Oral Anticoagulants (DOACs) Industry Trends Table 25. Direct Oral Anticoagulants (DOACs) Industry Drivers Table 26. Direct Oral Anticoagulants (DOACs) Industry Opportunities and Challenges Table 27. Direct Oral Anticoagulants (DOACs) Industry Restraints Table 28. Global Direct Oral Anticoagulants (DOACs) Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Direct Oral Anticoagulants (DOACs) Revenue Market Share by Company (2021-2026) Table 30. Global Direct Oral Anticoagulants (DOACs) Sales by Company (2021-2026) & (K Units) Table 31. Global Direct Oral Anticoagulants (DOACs) Sales Share by Company (2021-2026) Table 32. Global Direct Oral Anticoagulants (DOACs) Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Direct Oral Anticoagulants (DOACs) Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Direct Oral Anticoagulants (DOACs) Major Company Production Sites and Headquarters Table 35. Global Direct Oral Anticoagulants (DOACs) Company, Product Type & Application Table 36. Global Direct Oral Anticoagulants (DOACs) Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Direct Oral Anticoagulants (DOACs) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Direct Oral Anticoagulants (DOACs) Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Direct Oral Anticoagulants (DOACs) Sales by Region (2021-2026) & (K Units) Table 41. Global Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Region (2021-2026) Table 42. Global Direct Oral Anticoagulants (DOACs) Sales by Region (2021-2026) & (US$ Million) Table 43. Global Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Region (2021-2026) Table 44. Global Direct Oral Anticoagulants (DOACs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Direct Oral Anticoagulants (DOACs) Sales by Region (2027-2032) & (K Units) Table 46. Global Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Region (2027-2032) Table 47. Global Direct Oral Anticoagulants (DOACs) Sales by Region (2027-2032) & (US$ Million) Table 48. Global Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Region (2027-2032) Table 49. Global Direct Oral Anticoagulants (DOACs) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units) Table 52. Global Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Application (2021-2026) Table 53. Global Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (US$ Million) Table 54. Global Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Application (2021-2026) Table 55. Global Direct Oral Anticoagulants (DOACs) Price by Application (2021-2026) & (US$/Unit) Table 56. Global Direct Oral Anticoagulants (DOACs) Sales by Application (2027-2032) & (K Units) Table 57. Global Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Application (2027-2032) Table 58. Global Direct Oral Anticoagulants (DOACs) Sales by Application (2027-2032) & (US$ Million) Table 59. Global Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Application (2027-2032) Table 60. Global Direct Oral Anticoagulants (DOACs) Price by Application (2027-2032) & (US$/Unit) Table 61. North America Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units) Table 62. North America Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units) Table 64. Europe Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units) Table 68. Latin America Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Application (2021-2026) & (US$ Million) Table 71. Accord Healthcare Company Information Table 72. Accord Healthcare Business Overview Table 73. Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolio Table 75. Accord Healthcare Recent Development Table 76. Apotex Company Information Table 77. Apotex Business Overview Table 78. Apotex Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Apotex Direct Oral Anticoagulants (DOACs) Product Portfolio Table 80. Apotex Recent Development Table 81. Boehringer Ingelheim Company Information Table 82. Boehringer Ingelheim Business Overview Table 83. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolio Table 85. Boehringer Ingelheim Recent Development Table 86. Bristol Myers Squibb Company Information Table 87. Bristol Myers Squibb Business Overview Table 88. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolio Table 90. Bristol Myers Squibb Recent Development Table 91. Daiichi Sankyo Company Information Table 92. Daiichi Sankyo Business Overview Table 93. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolio Table 95. Daiichi Sankyo Recent Development Table 96. GlaxoSmithKline Company Information Table 97. GlaxoSmithKline Business Overview Table 98. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolio Table 100. GlaxoSmithKline Recent Development Table 101. Janssen Pharmaceuticals Company Information Table 102. Janssen Pharmaceuticals Business Overview Table 103. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolio Table 105. Janssen Pharmaceuticals Recent Development Table 106. Teva Pharmaceutical Company Information Table 107. Teva Pharmaceutical Business Overview Table 108. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolio Table 110. Teva Pharmaceutical Recent Development Table 111. Viatris Company Information Table 112. Viatris Business Overview Table 113. Viatris Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Viatris Direct Oral Anticoagulants (DOACs) Product Portfolio Table 115. Viatris Recent Development Table 116. Bayer Company Information Table 117. Bayer Business Overview Table 118. Bayer Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Bayer Direct Oral Anticoagulants (DOACs) Product Portfolio Table 120. Bayer Recent Development Table 121. Pfizer Company Information Table 122. Pfizer Business Overview Table 123. Pfizer Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolio Table 125. Pfizer Recent Development Table 126. Mylan Company Information Table 127. Mylan Business Overview Table 128. Mylan Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Mylan Direct Oral Anticoagulants (DOACs) Product Portfolio Table 130. Mylan Recent Development Table 131. Sandoz Company Information Table 132. Sandoz Business Overview Table 133. Sandoz Direct Oral Anticoagulants (DOACs) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolio Table 135. Sandoz Recent Development Table 136. North America Direct Oral Anticoagulants (DOACs) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 137. North America Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units) Table 138. North America Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021-2026) Table 139. North America Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032) & (K Units) Table 140. North America Direct Oral Anticoagulants (DOACs) Sales Market Share Forecast by Country (2027-2032) Table 141. North America Direct Oral Anticoagulants (DOACs) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 142. North America Direct Oral Anticoagulants (DOACs) Market Size by Country (2021-2026) & (US$ Million) Table 143. North America Direct Oral Anticoagulants (DOACs) Market Share by Country (2021-2026) Table 144. North America Direct Oral Anticoagulants (DOACs) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 145. North America Direct Oral Anticoagulants (DOACs) Market Share Forecast by Country (2027-2032) Table 146. Europe Direct Oral Anticoagulants (DOACs) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 147. Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units) Table 148. Europe Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021-2026) Table 149. Europe Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032) & (K Units) Table 150. Europe Direct Oral Anticoagulants (DOACs) Sales Market Share Forecast by Country (2027-2032) Table 151. Europe Direct Oral Anticoagulants (DOACs) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 152. Europe Direct Oral Anticoagulants (DOACs) Market Size by Country (2021-2026) & (US$ Million) Table 153. Europe Direct Oral Anticoagulants (DOACs) Market Share by Country (2021-2026) Table 154. Europe Direct Oral Anticoagulants (DOACs) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 155. Europe Direct Oral Anticoagulants (DOACs) Market Share Forecast by Country (2027-2032) Table 156. Asia-Pacific Direct Oral Anticoagulants (DOACs) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 157. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units) Table 158. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021-2026) Table 159. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032) & (K Units) Table 160. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Market Share Forecast by Country (2027-2032) Table 161. Asia-Pacific Direct Oral Anticoagulants (DOACs) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 162. Asia-Pacific Direct Oral Anticoagulants (DOACs) Market Size by Country (2021-2026) & (US$ Million) Table 163. Asia-Pacific Direct Oral Anticoagulants (DOACs) Market Share by Country (2021-2026) Table 164. Asia-Pacific Direct Oral Anticoagulants (DOACs) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 165. Asia-Pacific Direct Oral Anticoagulants (DOACs) Market Share Forecast by Country (2027-2032) Table 166. Latin America Direct Oral Anticoagulants (DOACs) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 167. Latin America Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units) Table 168. Latin America Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021-2026) Table 169. Latin America Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032) & (K Units) Table 170. Latin America Direct Oral Anticoagulants (DOACs) Sales Market Share Forecast by Country (2027-2032) Table 171. Latin America Direct Oral Anticoagulants (DOACs) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 172. Latin America Direct Oral Anticoagulants (DOACs) Market Size by Country (2021-2026) & (US$ Million) Table 173. Latin America Direct Oral Anticoagulants (DOACs) Market Share by Country (2021-2026) Table 174. Latin America Direct Oral Anticoagulants (DOACs) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 175. Latin America Direct Oral Anticoagulants (DOACs) Market Share Forecast by Country (2027-2032) Table 176. Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 177. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026) & (K Units) Table 178. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Market Share by Country (2021-2026) Table 179. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032) & (K Units) Table 180. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Market Share Forecast by Country (2027-2032) Table 181. Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 182. Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Size by Country (2021-2026) & (US$ Million) Table 183. Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Share by Country (2021-2026) Table 184. Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Size Forecast by Country (2027-2032) & (US$ Million) Table 185. Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Share Forecast by Country (2027-2032) Table 186. Key Raw Materials Table 187. Raw Materials Key Suppliers Table 188. Direct Oral Anticoagulants (DOACs) Distributors List Table 189. Direct Oral Anticoagulants (DOACs) Customers List Table 190. Research Programs/Design for This Report Table 191. Authors List of This Report Table 192. Secondary Sources Table 193. Primary Sources List of Figures Figure 1. Direct Oral Anticoagulants (DOACs) Image Figure 2. Global Direct Oral Anticoagulants (DOACs) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Direct Oral Anticoagulants (DOACs) Market Size (2021-2032) & (US$ Million) Figure 4. Global Direct Oral Anticoagulants (DOACs) Sales (2021-2032) & (K Units) Figure 5. Oral Factor Xa Inhibitors Image Figure 6. Global Oral Factor Xa Inhibitors Sales YoY Growth (2021-2032) & (K Units) Figure 7. Direct Thrombin Inhibitors (DTIs) Image Figure 8. Global Direct Thrombin Inhibitors (DTIs) Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Direct Oral Anticoagulants (DOACs) Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Direct Oral Anticoagulants (DOACs) Market Share by Type 2025 VS 2032 Figure 11. North America Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Type in 2025 Figure 12. North America Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Type in 2025 Figure 13. Europe Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Type in 2025 Figure 14. Europe Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Type in 2025 Figure 17. Latin America Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Direct Oral Anticoagulants (DOACs) Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Pulmonary Embolism Image Figure 24. Global Pulmonary Embolism Sales YoY Growth (2021-2032) & (K Units) Figure 25. Deep Vein Thrombosis Image Figure 26. Global Deep Vein Thrombosis Sales YoY Growth (2021-2032) & (K Units) Figure 27. Atrial Fibrillation Image Figure 28. Global Atrial Fibrillation Sales YoY Growth (2021-2032) & (K Units) Figure 29. Other Image Figure 30. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 31. Global Direct Oral Anticoagulants (DOACs) Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Direct Oral Anticoagulants (DOACs) Market Share by Application 2025 VS 2032 Figure 33. North America Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Application in 2025 Figure 34. North America Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Application in 2025 Figure 35. Europe Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Application in 2025 Figure 36. Europe Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Application in 2025 Figure 39. Latin America Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Market Share in Value by Application in 2025 Figure 43. North America Direct Oral Anticoagulants (DOACs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 44. North America Direct Oral Anticoagulants (DOACs) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Direct Oral Anticoagulants (DOACs) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Direct Oral Anticoagulants (DOACs) Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Direct Oral Anticoagulants (DOACs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. Europe Direct Oral Anticoagulants (DOACs) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Direct Oral Anticoagulants (DOACs) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Direct Oral Anticoagulants (DOACs) Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Direct Oral Anticoagulants (DOACs) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Direct Oral Anticoagulants (DOACs) Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Direct Oral Anticoagulants (DOACs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Latin America Direct Oral Anticoagulants (DOACs) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Direct Oral Anticoagulants (DOACs) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Direct Oral Anticoagulants (DOACs) Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Direct Oral Anticoagulants (DOACs) Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Direct Oral Anticoagulants (DOACs) Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Factor Xa Inhibitors
  • Direct Thrombin Inhibitors (DTIs)
Applications
  • Pulmonary Embolism
  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Other
Companies covered
  • Accord Healthcare
  • Apotex
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Daiichi Sankyo
  • GlaxoSmithKline
  • Janssen Pharmaceuticals
  • Teva Pharmaceutical
  • Viatris
  • Bayer
  • Pfizer
  • Mylan
  • Sandoz

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Direct Oral Anticoagulants (DOACs) Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Direct Oral Anticoagulants (DOACs) Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Direct Oral Anticoagulants (DOACs) Market by Type
  6. 1.3.1 Oral Factor Xa Inhibitors
  7. 1.3.2 Direct Thrombin Inhibitors (DTIs)
  8. 1.4 Global Direct Oral Anticoagulants (DOACs) Market Size by Type
  9. 1.4.1 Global Direct Oral Anticoagulants (DOACs) Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Direct Oral Anticoagulants (DOACs) Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Direct Oral Anticoagulants (DOACs) Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Direct Oral Anticoagulants (DOACs) Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Direct Oral Anticoagulants (DOACs) Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Direct Oral Anticoagulants (DOACs) Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Direct Oral Anticoagulants (DOACs) Industry Trends
  2. 2.2 Direct Oral Anticoagulants (DOACs) Industry Drivers
  3. 2.3 Direct Oral Anticoagulants (DOACs) Industry Opportunities and Challenges
  4. 2.4 Direct Oral Anticoagulants (DOACs) Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Direct Oral Anticoagulants (DOACs) Revenue (2021-2026)
  2. 3.2 Global Top Players by Direct Oral Anticoagulants (DOACs) Sales (2021-2026)
  3. 3.3 Global Top Players by Direct Oral Anticoagulants (DOACs) Price (2021-2026)
  4. 3.4 Global Direct Oral Anticoagulants (DOACs) Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Direct Oral Anticoagulants (DOACs) Major Company Production Sites & Headquarters
  6. 3.6 Global Direct Oral Anticoagulants (DOACs) Company, Product Type & Application
  7. 3.7 Global Direct Oral Anticoagulants (DOACs) Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Direct Oral Anticoagulants (DOACs) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Direct Oral Anticoagulants (DOACs) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Direct Oral Anticoagulants (DOACs) Tier 1, Tier 2, and Tier 3
4 Direct Oral Anticoagulants (DOACs) Regional Status and Outlook
  1. 4.1 Global Direct Oral Anticoagulants (DOACs) Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Direct Oral Anticoagulants (DOACs) Historic Market Size by Region
  3. 4.2.1 Global Direct Oral Anticoagulants (DOACs) Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Direct Oral Anticoagulants (DOACs) Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Direct Oral Anticoagulants (DOACs) Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Direct Oral Anticoagulants (DOACs) Forecasted Market Size by Region
  7. 4.3.1 Global Direct Oral Anticoagulants (DOACs) Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Direct Oral Anticoagulants (DOACs) Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Direct Oral Anticoagulants (DOACs) Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Direct Oral Anticoagulants (DOACs) by Application
  1. 5.1 Direct Oral Anticoagulants (DOACs) Market by Application
  2. 5.1.1 Pulmonary Embolism
  3. 5.1.2 Deep Vein Thrombosis
  4. 5.1.3 Atrial Fibrillation
  5. 5.1.4 Other
  6. 5.2 Global Direct Oral Anticoagulants (DOACs) Market Size by Application
  7. 5.2.1 Global Direct Oral Anticoagulants (DOACs) Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Direct Oral Anticoagulants (DOACs) Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Direct Oral Anticoagulants (DOACs) Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Direct Oral Anticoagulants (DOACs) Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Direct Oral Anticoagulants (DOACs) Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Direct Oral Anticoagulants (DOACs) Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Accord Healthcare
  2. 6.1.1 Accord Healthcare Company Information
  3. 6.1.2 Accord Healthcare Business Overview
  4. 6.1.3 Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolio
  6. 6.1.5 Accord Healthcare Recent Developments
  7. 6.2 Apotex
  8. 6.2.1 Apotex Company Information
  9. 6.2.2 Apotex Business Overview
  10. 6.2.3 Apotex Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Apotex Direct Oral Anticoagulants (DOACs) Product Portfolio
  12. 6.2.5 Apotex Recent Developments
  13. 6.3 Boehringer Ingelheim
  14. 6.3.1 Boehringer Ingelheim Company Information
  15. 6.3.2 Boehringer Ingelheim Business Overview
  16. 6.3.3 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolio
  18. 6.3.5 Boehringer Ingelheim Recent Developments
  19. 6.4 Bristol Myers Squibb
  20. 6.4.1 Bristol Myers Squibb Company Information
  21. 6.4.2 Bristol Myers Squibb Business Overview
  22. 6.4.3 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolio
  24. 6.4.5 Bristol Myers Squibb Recent Developments
  25. 6.5 Daiichi Sankyo
  26. 6.5.1 Daiichi Sankyo Company Information
  27. 6.5.2 Daiichi Sankyo Business Overview
  28. 6.5.3 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolio
  30. 6.5.5 Daiichi Sankyo Recent Developments
  31. 6.6 GlaxoSmithKline
  32. 6.6.1 GlaxoSmithKline Company Information
  33. 6.6.2 GlaxoSmithKline Business Overview
  34. 6.6.3 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolio
  36. 6.6.5 GlaxoSmithKline Recent Developments
  37. 6.7 Janssen Pharmaceuticals
  38. 6.7.1 Janssen Pharmaceuticals Company Information
  39. 6.7.2 Janssen Pharmaceuticals Business Overview
  40. 6.7.3 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolio
  42. 6.7.5 Janssen Pharmaceuticals Recent Developments
  43. 6.8 Teva Pharmaceutical
  44. 6.8.1 Teva Pharmaceutical Company Information
  45. 6.8.2 Teva Pharmaceutical Business Overview
  46. 6.8.3 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolio
  48. 6.8.5 Teva Pharmaceutical Recent Developments
  49. 6.9 Viatris
  50. 6.9.1 Viatris Company Information
  51. 6.9.2 Viatris Business Overview
  52. 6.9.3 Viatris Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Viatris Direct Oral Anticoagulants (DOACs) Product Portfolio
  54. 6.9.5 Viatris Recent Developments
  55. 6.10 Bayer
  56. 6.10.1 Bayer Company Information
  57. 6.10.2 Bayer Business Overview
  58. 6.10.3 Bayer Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Bayer Direct Oral Anticoagulants (DOACs) Product Portfolio
  60. 6.10.5 Bayer Recent Developments
  61. 6.11 Pfizer
  62. 6.11.1 Pfizer Company Information
  63. 6.11.2 Pfizer Business Overview
  64. 6.11.3 Pfizer Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolio
  66. 6.11.5 Pfizer Recent Developments
  67. 6.12 Mylan
  68. 6.12.1 Mylan Company Information
  69. 6.12.2 Mylan Business Overview
  70. 6.12.3 Mylan Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Mylan Direct Oral Anticoagulants (DOACs) Product Portfolio
  72. 6.12.5 Mylan Recent Developments
  73. 6.13 Sandoz
  74. 6.13.1 Sandoz Company Information
  75. 6.13.2 Sandoz Business Overview
  76. 6.13.3 Sandoz Direct Oral Anticoagulants (DOACs) Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolio
  78. 6.13.5 Sandoz Recent Developments
7 North America by Country
  1. 7.1 North America Direct Oral Anticoagulants (DOACs) Sales by Country
  2. 7.1.1 North America Direct Oral Anticoagulants (DOACs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026)
  4. 7.1.3 North America Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032)
  5. 7.2 North America Direct Oral Anticoagulants (DOACs) Market Size by Country
  6. 7.2.1 North America Direct Oral Anticoagulants (DOACs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Direct Oral Anticoagulants (DOACs) Market Size by Country (2021-2026)
  8. 7.2.3 North America Direct Oral Anticoagulants (DOACs) Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Direct Oral Anticoagulants (DOACs) Sales by Country
  2. 8.1.1 Europe Direct Oral Anticoagulants (DOACs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026)
  4. 8.1.3 Europe Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Direct Oral Anticoagulants (DOACs) Market Size by Country
  6. 8.2.1 Europe Direct Oral Anticoagulants (DOACs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Direct Oral Anticoagulants (DOACs) Market Size by Country (2021-2026)
  8. 8.2.3 Europe Direct Oral Anticoagulants (DOACs) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales by Country
  2. 9.1.1 Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Direct Oral Anticoagulants (DOACs) Market Size by Country
  6. 9.2.1 Asia-Pacific Direct Oral Anticoagulants (DOACs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Direct Oral Anticoagulants (DOACs) Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Direct Oral Anticoagulants (DOACs) Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Direct Oral Anticoagulants (DOACs) Sales by Country
  2. 10.1.1 South America Direct Oral Anticoagulants (DOACs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026)
  4. 10.1.3 South America Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032)
  5. 10.2 South America Direct Oral Anticoagulants (DOACs) Market Size by Country
  6. 10.2.1 South America Direct Oral Anticoagulants (DOACs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Direct Oral Anticoagulants (DOACs) Market Size by Country (2021-2026)
  8. 10.2.3 South America Direct Oral Anticoagulants (DOACs) Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Country
  2. 11.1.1 Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Direct Oral Anticoagulants (DOACs) Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Size by Country
  6. 11.2.1 Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Direct Oral Anticoagulants (DOACs) Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Direct Oral Anticoagulants (DOACs) Value Chain Analysis
  2. 12.1.1 Direct Oral Anticoagulants (DOACs) Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Direct Oral Anticoagulants (DOACs) Production Mode & Process
  7. 12.2 Direct Oral Anticoagulants (DOACs) Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Direct Oral Anticoagulants (DOACs) Distributors
  10. 12.2.3 Direct Oral Anticoagulants (DOACs) Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst